{
    "clinical_study": {
        "@rank": "152844", 
        "arm_group": [
            {
                "arm_group_label": "moxifloxacin, pill", 
                "arm_group_type": "Experimental", 
                "description": "Oral dose of 400mg moxifloxacin"
            }, 
            {
                "arm_group_label": "moxifloxacin-placebo,pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A pill of moxifloxacin-placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A single-center, randomized, double-blinded, 2-way crossover, placebo-controlled study to\n      assess  the QTc interval after administration of single oral dose of 400mg Moxifloxacin  in\n      healthy Chinese subjects."
        }, 
        "brief_title": "Moxifloxacin_QT Study in Chinese Healthy Volunteer", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "QT Interval Prolongation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy Chinese subjects, male, 20 to 45 years of age included, and in good health as\n             determined by past medical history, physical examination, vital signs,\n             electrocardiogram, and laboratory tests at screening.\n\n          2. At Screening, vital signs (systolic and diastolic blood pressure and pulse rate) will\n             be assessed in the sitting position after the subject has rested for 5 minutes. All\n             of vital signs should be within normal ranges:\n\n               -  Body temperature (Body) between 35.0-37.0\u00b0C\n\n               -  90 \u2264 systolic blood pressure <140 mm Hg\n\n               -  60\u2264 diastolic blood pressure < 90 mm Hg\n\n               -  50\u2264 pulse rate \u2264 100\n\n          3. Body weight need to be at least 50kg or above, 19kg/m2\u2264 Body Mass Index(BMI) \u226425kg/m2\n\n          4. Be able to communicate well with the investigator, to understand and comply with the\n             requirements of the study. Understand and sign the written informed consent prior to\n             any screening procedures.\n\n        Exclusion Criteria:\n\n          1. History or clinical manifestations of significant metabolic, hepatic, renal,\n             hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological,\n             genetic or psychiatric disorders.\n\n          2. A past medical history of clinically significant ECG abnormalities or a family\n             history (grandparents, parents and siblings) of long QT syndrome, or QTc interval >\n             440 ms for male or any abnormal ECG findings at screening.\n\n          3. Medical histories of syncope, electrophysiological changes, heart failure, reduced\n             exercise tolerance, cardiomyopathy, pericarditis, myocarditis or other cardiac\n             disorders as determined by the investigator.\n\n          4. Current electrolyte abnormalities (specifically hypokalemia) in laboratory\n             examination during the screening that are clinical significant as determined by\n             investigator.\n\n          5. Current or recent history (< 30 days prior to Screening) of a clinically significant\n             illness.\n\n          6. Use of any prescription drugs, herbal supplements, within 4 weeks prior to initial\n             dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins\n             included) within 4 week prior to initial dosing.\n\n          7. Positive results of human immunodeficiency virus, Hepatitis B surface antigen or\n             Hepatitis C antibody testing.\n\n          8. History of any hypersensitivity or allergic reaction of moxifloxacin or other types\n             fluoroquinolones.\n\n          9. Use of tobacco or history of use of tobacco ( > 5 tobacco/week) or\n             nicotine-containing products in the 3 months prior to screening.\n\n         10. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of\n             such abuse as indicated by the laboratory assays conducted during the screening\n             and/or at baseline.\n\n         11. Dosing of study drug in any clinical investigation within 3 months prior to initial\n             dosing.\n\n         12. Donation or loss of 200 ml or more of blood within 3 months prior to participation,\n             or donation of component blood within 3 months prior to participation.\n\n         13. Consumption of alcohol-, caffeine --containing foods or beverages within 48 hours\n             preceding study drug administration.\n\n         14. Other conditions which investigator deems potential harm to subjects if participate\n             the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653990", 
            "org_study_id": "DCTC_2012001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "moxifloxacin, pill", 
                    "moxifloxacin-placebo,pill"
                ], 
                "description": "oral dose of 400mg moxifloxacin", 
                "intervention_name": "moxifloxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "moxifloxacin, pill", 
                    "moxifloxacin-placebo,pill"
                ], 
                "description": "Oral dose of a pill of moxifloxacin-placebo", 
                "intervention_name": "moxifloxacin-placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 30, 2012", 
        "location": {
            "contact": {
                "email": "haianli1027@hotmail.com", 
                "last_name": "Haiyan Li, MD", 
                "phone": "861082266226"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100191"
                }, 
                "name": "Peking University Third Hospital Drug Clinical Trial Center"
            }, 
            "investigator": {
                "last_name": "Jingchuan Guo, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study to Assess the QT/QTc Interval After Administration of Single Oral Dose of 400mg Moxifloxacin in Healthy Chinese Subjects", 
        "overall_contact": {
            "email": "guojingchuan1029@126.com", 
            "last_name": "Jingchuan Guo, MD", 
            "phone": "861082265509"
        }, 
        "overall_contact_backup": {
            "email": "haiyanli1027@hotmail.com", 
            "last_name": "Haiyan Li, MD", 
            "phone": "861082266226"
        }, 
        "overall_official": {
            "affiliation": "Peking University Third Hospital", 
            "last_name": "Haiyan Li, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "baseline-adjusted, placebo-corrected effect on QTcF (\u0394\u0394QTcF)", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653990"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University Third Hospital", 
            "investigator_full_name": "Haiyan Li", 
            "investigator_title": "Director of Drug Clinical Trial Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Heart rate, PR, QRS, QTcB and QTcI", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "source": "Peking University Third Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University Third Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}